216 related articles for article (PubMed ID: 24668328)
1. Determination of prognostic factors in Japanese patients with advanced gastric cancer using the data from a randomized controlled trial, Japan clinical oncology group 9912.
Takahari D; Boku N; Mizusawa J; Takashima A; Yamada Y; Yoshino T; Yamazaki K; Koizumi W; Fukase K; Yamaguchi K; Goto M; Nishina T; Tamura T; Tsuji A; Ohtsu A
Oncologist; 2014 Apr; 19(4):358-66. PubMed ID: 24668328
[TBL] [Abstract][Full Text] [Related]
2. Impact of excision repair cross-complementing gene 1 (ERCC1) on the outcomes of patients with advanced gastric cancer: correlative study in Japan Clinical Oncology Group Trial JCOG9912.
Yamada Y; Boku N; Nishina T; Yamaguchi K; Denda T; Tsuji A; Hamamoto Y; Konishi K; Tsuji Y; Amagai K; Ohkawa S; Fujita Y; Nishisaki H; Kawai H; Takashima A; Mizusawa J; Nakamura K; Ohtsu A
Ann Oncol; 2013 Oct; 24(10):2560-2565. PubMed ID: 23884439
[TBL] [Abstract][Full Text] [Related]
3. Survival prolongation after treatment failure of first-line chemotherapy in patients with advanced gastric cancer: combined analysis of the Japan Clinical Oncology group trials JCOG9205 and JCOG9912.
Takashima A; Boku N; Kato K; Nakamura K; Mizusawa J; Fukuda H; Shirao K; Shimada Y; Ohtsu A
Gastric Cancer; 2014; 17(3):522-8. PubMed ID: 24162387
[TBL] [Abstract][Full Text] [Related]
4. Validation of the JCOG prognostic index in advanced gastric cancer using individual patient data from the SPIRITS and G-SOX trials.
Takahari D; Mizusawa J; Koizumi W; Hyodo I; Boku N
Gastric Cancer; 2017 Sep; 20(5):757-763. PubMed ID: 28205060
[TBL] [Abstract][Full Text] [Related]
5. Fluorouracil versus combination of irinotecan plus cisplatin versus S-1 in metastatic gastric cancer: a randomised phase 3 study.
Boku N; Yamamoto S; Fukuda H; Shirao K; Doi T; Sawaki A; Koizumi W; Saito H; Yamaguchi K; Takiuchi H; Nasu J; Ohtsu A;
Lancet Oncol; 2009 Nov; 10(11):1063-9. PubMed ID: 19818685
[TBL] [Abstract][Full Text] [Related]
6. Long-term survival and prognostic factors in patients with metastatic gastric cancers treated with chemotherapy in the Japan Clinical Oncology Group (JCOG) study.
Yoshida M; Ohtsu A; Boku N; Miyata Y; Shirao K; Shimada Y; Hyodo I; Koizumi W; Kurihara M; Yoshida S; Yamamoto S
Jpn J Clin Oncol; 2004 Nov; 34(11):654-9. PubMed ID: 15613554
[TBL] [Abstract][Full Text] [Related]
7. Phase II/III study of second-line chemotherapy comparing irinotecan-alone with S-1 plus irinotecan in advanced gastric cancer refractory to first-line treatment with S-1 (JACCRO GC-05).
Tanabe K; Fujii M; Nishikawa K; Kunisaki C; Tsuji A; Matsuhashi N; Takagane A; Ohno T; Kawase T; Kochi M; Yoshida K; Kakeji Y; Ichikawa W; Chin K; Terashima M; Takeuchi M; Nakajima T
Ann Oncol; 2015 Sep; 26(9):1916-1922. PubMed ID: 26109630
[TBL] [Abstract][Full Text] [Related]
8. Second-line irinotecan after cisplatin, fluoropyrimidin and docetaxel for chemotherapy of metastatic gastric cancer.
Kucukzeybek Y; Dirican A; Erten C; Somali I; Can A; Demir L; Bayoglu IV; Akyol M; Medeni M; Tarhan MO
Asian Pac J Cancer Prev; 2012; 13(6):2771-4. PubMed ID: 22938457
[TBL] [Abstract][Full Text] [Related]
9. Modified FOLFOX-6 therapy for heavily pretreated advanced gastric cancer refractory to fluorouracil, irinotecan, cisplatin and taxanes: a retrospective study.
Tsuji K; Yasui H; Onozawa Y; Boku N; Doyama H; Fukutomi A; Yamazaki K; Machida N; Todaka A; Taniguchi H; Tsushima T; Yokota T
Jpn J Clin Oncol; 2012 Aug; 42(8):686-90. PubMed ID: 22693245
[TBL] [Abstract][Full Text] [Related]
10. Docetaxel/cisplatin followed by FOLFIRI versus the reverse sequence in metastatic gastric cancer.
Kim JA; Lee J; Han B; Park SH; Park JO; Park YS; Lim HY; Kang WK
Cancer Chemother Pharmacol; 2011 Jul; 68(1):177-84. PubMed ID: 20878159
[TBL] [Abstract][Full Text] [Related]
11. Combination chemotherapy with capecitabine (X) and Cisplatin (P) as first line treatment in advanced gastric cancer: experience of 223 patients with prognostic factor analysis.
Lee SS; Lee JL; Ryu MH; Chang HM; Kim TW; Kang HJ; Kim WK; Lee JS; Kang YK
Jpn J Clin Oncol; 2007 Jan; 37(1):30-7. PubMed ID: 17272321
[TBL] [Abstract][Full Text] [Related]
12. Second-line chemotherapy with irinotecan plus cisplatin after the failure of S-1 monotherapy for advanced gastric cancer.
Takahari D; Shimada Y; Takeshita S; Nishitani H; Takashima A; Okita N; Hirashima Y; Kato K; Hamaguchi T; Yamada Y; Shirao K
Gastric Cancer; 2010 Aug; 13(3):186-90. PubMed ID: 20820988
[TBL] [Abstract][Full Text] [Related]
13. Randomised phase III trial of second-line irinotecan plus cisplatin versus irinotecan alone in patients with advanced gastric cancer refractory to S-1 monotherapy: TRICS trial.
Nishikawa K; Fujitani K; Inagaki H; Akamaru Y; Tokunaga S; Takagi M; Tamura S; Sugimoto N; Shigematsu T; Yoshikawa T; Ishiguro T; Nakamura M; Morita S; Miyashita Y; Tsuburaya A; Sakamoto J; Tsujinaka T
Eur J Cancer; 2015 May; 51(7):808-16. PubMed ID: 25797356
[TBL] [Abstract][Full Text] [Related]
14. A retrospective analysis of second-line chemotherapy in patients with advanced gastric cancer.
Ji SH; Lim DH; Yi SY; Kim HS; Jun HJ; Kim KH; Chang MH; Park MJ; Uhm JE; Lee J; Park SH; Park JO; Park YS; Lim HY; Kang WK
BMC Cancer; 2009 Apr; 9():110. PubMed ID: 19358705
[TBL] [Abstract][Full Text] [Related]
15. Randomized phase III trial of fluorouracil alone versus fluorouracil plus cisplatin versus uracil and tegafur plus mitomycin in patients with unresectable, advanced gastric cancer: The Japan Clinical Oncology Group Study (JCOG9205).
Ohtsu A; Shimada Y; Shirao K; Boku N; Hyodo I; Saito H; Yamamichi N; Miyata Y; Ikeda N; Yamamoto S; Fukuda H; Yoshida S;
J Clin Oncol; 2003 Jan; 21(1):54-9. PubMed ID: 12506170
[TBL] [Abstract][Full Text] [Related]
16. Long-term outcomes and prognostic factors of patients with advanced gastric cancer treated with S-1 plus cisplatin combination chemotherapy as a first-line treatment.
Kadowaki S; Komori A; Narita Y; Nitta S; Yamaguchi K; Kondo C; Taniguchi H; Takahari D; Ura T; Ando M; Muro K
Int J Clin Oncol; 2014 Aug; 19(4):656-61. PubMed ID: 23999902
[TBL] [Abstract][Full Text] [Related]
17. Biweekly irinotecan plus cisplatin versus irinotecan alone as second-line treatment for advanced gastric cancer: a randomised phase III trial (TCOG GI-0801/BIRIP trial).
Higuchi K; Tanabe S; Shimada K; Hosaka H; Sasaki E; Nakayama N; Takeda Y; Moriwaki T; Amagai K; Sekikawa T; Sakuyama T; Kanda T; Sasaki T; Azuma M; Takahashi F; Takeuchi M; Koizumi W;
Eur J Cancer; 2014 May; 50(8):1437-45. PubMed ID: 24560487
[TBL] [Abstract][Full Text] [Related]
18. Second-line chemotherapy for advanced gastric cancer in Korea.
Baek SK; Kim SY; Jeong JH; Cho KS; Yoon HJ
Gastric Cancer; 2012 Oct; 15(4):345-54. PubMed ID: 22410800
[TBL] [Abstract][Full Text] [Related]
19. Gastrectomy plus chemotherapy versus chemotherapy alone for advanced gastric cancer with a single non-curable factor (REGATTA): a phase 3, randomised controlled trial.
Fujitani K; Yang HK; Mizusawa J; Kim YW; Terashima M; Han SU; Iwasaki Y; Hyung WJ; Takagane A; Park DJ; Yoshikawa T; Hahn S; Nakamura K; Park CH; Kurokawa Y; Bang YJ; Park BJ; Sasako M; Tsujinaka T;
Lancet Oncol; 2016 Mar; 17(3):309-318. PubMed ID: 26822397
[TBL] [Abstract][Full Text] [Related]
20. Past and present achievements, and future direction of the Gastrointestinal Oncology Study Group (GIOSG), a Division of Japan Clinical Oncology Group (JCOG).
Boku N
Jpn J Clin Oncol; 2011 Dec; 41(12):1315-21. PubMed ID: 21980051
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
